Our Partners > Platinum Sponsor 2014
Boston Scientific’s VerciseTM Deep Brain Stimulation (DBS) system provides therapy that helps reduce some of the symptoms associated with Parkinson’s disease. DBS utilizes a surgically implanted medical device that works by stimulating a targeted area in the brain. The stimulation can be adjusted by your physician to optimize your therapy to help control your symptoms. The stimulator also contains a rechargeable battery.
The Vercise™ DBS System received CE mark and TGA approval for the treatment of Parkinson’s disease. It is approved for sale in the EU, Israel, and Australia. The Vercise DBS System is also CE marked for the treatment of primary and secondary Dystonia and is approved for use in the EU. In the U.S., the Vercise DBS System is investigational and not available for sale. The INTREPID US DBS study is currently investigating the safety and effectiveness of the VerciseTM DBS system in patients with Parkinson’s disease. Learn more at www.bostonscientific.com.
LSVT Global is a socially responsible business with a mission to empower people with Parkinson's disease (PD) through evidence-based speech, physical and occupational therapy programs. LSVT Global seeks to translate clinical treatment research directly to public health practice and increase accessibility of LSVT to people living with PD. To date, LSVT Global has trained over 13,000 speech, physical and occupational therapists in 54 countries in LSVT protocols. LSVT LOUD™ speech treatment is now available in your home through the LSVT Companion System and via telemedicine through LSVT eLOUD. LSVT BIG™ physical/occupational therapy is growing in availability and has improved movement and quality of life of people with PD. During the Unity Walk, there will be experts in speech, physical and occupational therapy for PD at the booth. You will see why this company is making an impact on the Parkinson's community. After visiting our booth, visit our website at www.LSVTGlobal.com.
DBS therapy uses a surgically implanted medical device, similar to a pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain. The stimulation can be programmed and adjusted non-invasively by a trained clinician to maximize symptom control and minimize side effects. More than 100,000 patients worldwide have received Medtronic DBS Therapy
The therapy is currently approved in many locations around the world, including Europe and the United States, for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease and chronic intractable primary dystonia, for which approval in the United States is under a Humanitarian Device Exemption (HDE). In Europe, Canada and Australia, DBS therapy is approved for the treatment of refractory epilepsy. DBS therapy is also approved for the treatment of severe, treatment-resistant obsessive-compulsive disorder in the European Union and Australia, and in the United States under an HDE.
MRI Interventions, Inc. is the developer of a minimally invasive neurosurgical platform, the ClearPoint® system, that enables “asleep” deep brain stimulation (DBS) lead placement. ClearPoint technology allows patients to experience a frameless DBS procedure, to sleep through the entire procedure and to continue regular medications through surgery. DBS surgery with the ClearPoint system may also involve fewer hospital visits for patients. The ClearPoint system uses MRI imaging to give surgeons a real-time view of the brain while they operate, eliminating the need for the patient to be awake. The ability to see the brain in real time allows the surgeon to precisely place the DBS lead at a location the size of a sesame seed in the brain. The ClearPoint system represents MRI Interventions’ commitment to developing surgical technologies with a focus on increasing patient comfort and improving patient outcomes.
Click for a printer friendly version